Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Cancer Immunol Res. 2016 Aug 22;4(10):869–880. doi: 10.1158/2326-6066.CIR-15-0230

Figure 6. Co-administration of ATRA with GD2-CAR T cells leads to enhanced antitumor efficacy against 143b osteosarcoma tumors in NSG mice.

Figure 6

(A) Tumor growth curves and (B) survival of NSG mice inoculated with 5 × 105 143b cells on day 0, followed by adoptive transfer of 30 × 106 untransduced-Mock or GD2-CAR T cells on day 3 and 15 × 106 on day 5. Where indicated, mice received ATRA pellets subcutaneously or sham surgeries day -1 before tumor injection. GD2-CAR T cells have enhanced antitumor effect and prolonged survival against 143b tumors in the presence of ATRA. n=3-5 mice/group. (C) Frequency of GD2-CAR+ expression within CD4+ (left) and CD8+ (right) T cells populations in the peripheral blood 15 days after adoptive transfer, assessed by flow cytometry. Adoptively transferred T cells distinguished from host murine cells by hCD45+. CAR+ identified by 1A7 anti-idiotype.